Skip to main content

Table 1 Published trials of hormonal therapy in ovarian cancer

From: The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole

Author [Ref] Treatment Study population Phase N ORR (%) CR (%) PR (%) SD (%) CBR (%)
Argenta, et al., 2009 [18] Fulvestrant Recurrent ER+ OC II 26 0 0 0 50 50
Ramirez, et al., 2008 [14] Letrozole 2.5 mg OD Recurrent ER+ high-grade OC, platinum- and taxane-resistant II 33 (31 evaluable by RECIST) 3 0 3 23 26
Smyth et al., 2007 [15] Letrozole 2.5 mg OD Recurrent ER+ OC II 44 (33 evaluable by RECIST) 9 0 9 42 51
Wagner, et al., 2007 [19] Tamoxifen 40 mg OD + gefitinib 500 mg OD Recurrent OC, platinum- and taxane resistant II 56 (49 evaluable by RECIST) 0 0 0 32.7 32.7
Papadimitriou, et al., 2004 [16] Letrozole 2.5 mg OD Recurrent OC II 27 (21 evaluable by WHO criteria) 15 5 10 19 29
del Carmen, et al., 2003 [20] Anastrozole 1 mg OD Recurrent OC II 53 1.9 0 1.9 42 43.9
Bowman, et al., 2002 [17] Letrozole 2.5 mg OD Recurrent OC II 60 (50 evaluable by UICC criteria) 0 0 0 17 17
Hatch, et al., 1991 [12] Tamoxifen 20 mg BD Recurrent OC II 105 17.1 9.5 7.6 38 45.6
Weiner, et al., 1987 [10] Tamoxifen 10 mg BD Recurrent OC II 37 (31 evaluable) 3.2 3.2 6.4 19.3 28.9
Schwartz, et al., 1982 [11] Tamoxifen 20 mg OD Recurrent OC II 13 7.4 0 7.7 30.8 38.5
  1. Abbreviations: BD twice daily, CBR clinical benefit rate, CR complete response, ER estrogen receptor, OC ovarian cancer, OD once daily, ORR objective response rate, PD progressive disease, PR partial response, SD stable disease